Pegcetacoplan has been approved for the treatment of C3 glomerulopathy or primary immune complex membranoproliferative ...

Medically reviewed by David Ozeri, MD C3G (Complement 3 Glomerulopathy) and IC-MPGN (Immune Complex Membranoproliferative ...

I’m excited to now have a highly effective therapy for a broad range of patients living with C3G and primary IC-MPGN,” said ...

This approval offers a promising new targeted treatment for patients aged 12 and older with C3 glomerulopathy (C3G) and primary immune complex membranoproliferative glomerulonephritis (IC-MPGN), ...

The FDA has approved Empaveli for the treatment of adult and pediatric patients aged 12 years and older with C3G or primary ...

Novartis and its Fabhalta may have been first to the punch in ultrarare kidney disease complement 3 glomerulopathy (C3G), but ...

Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) saw its stock soar 12% after the U.S. Food and Drug Administration (FDA) granted ...

The FDA approved pegcetacoplan (Empaveli; Apellis Pharmaceuticals) as the first treatment for patients 12 years and older with the rare, severe kidney diseases C3 glomerulopathy (C3G) and primary ...

Approval is based on results from the Phase III VALIANT trial (NCT05067127), in which Empaveli demonstrated a 68% reduction ...

Received U.S. FDA approval for EMPAVELI® (pegcetacoplan) for treatment of patients 12 years and older with C3G and primary IC-MPGNAnnounced capped royalty purchase agreement with Sobi under which ...

Results consistent across subgroups including C3G and primary IC-MPGN, adolescent and adult patients, and native and post-transplant kidneys STOCKHOLM, Oct. 27, 2024 /PRNewswire/ -- Sobi® (STO ...

DelveInsight's“ IC-MPGN – Market Insights, Epidemiology, and Market Forecast – 2034 ” delivers a deep dive analysis of the evolving disease landscape, highlighting epidemiological patterns ...